UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,712	05/15/2006	Christian Hesslinger	27319U	6309
	7590 05/29/200 OCIATES PLLC	EXAMINER		
112 South West	Street	SZNAIDMAN, MARCOS L		
Alexandria, VA 22314			ART UNIT	PAPER NUMBER
			1612	
			MAIL DATE	DELIVERY MODE
			05/29/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/576,712	HESSLINGER ET AL.	
Examiner	Art Unit	
MARCOS SZNAIDMAN	1612	

MARCOS SZNAIDMAN 16	612
The MAILING DATE of this communication appears on the cover sheet with the corr	respondence address
THE REPLY FILED <u>04 May 2009</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLO	OWANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of App application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed with periods:	peal. To avoid abandonment of this r other evidence, which places the h 37 CFR 41.31; or (3) a Request
<ul> <li>a) The period for reply expires 4 months from the mailing date of the final rejection.</li> <li>b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRM MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).</li> </ul>	ate of the final rejection.
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a have been filed is the date for purposes of determining the period of extension and the corresponding amount of the under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL	ne fee. The appropriate extension fee y set in the final Office action; or (2) as
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avo Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFF AMENDMENTS	oid dismissal of the appeal. Since a
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will  (a) They raise new issues that would require further consideration and/or search (see NOTE below);  (b) They raise the issue of new matter (see NOTE below);  (c) They are not deemed to place the application in better form for appeal by materially reduci appeal; and/or	below); ing or simplifying the issues for
<ul> <li>(d) They present additional claims without canceling a corresponding number of finally rejected NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).</li> <li>4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliance with 37 CFR 1.121.</li> </ul>	
<ul> <li>5. Applicant's reply has overcome the following rejection(s):</li> <li>6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, time non-allowable claim(s).</li> </ul>	ely filed amendment canceling the
7.  For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-7 and 11-15. Claim(s) withdrawn from consideration:	e entered and an explanation of
AFFIDAVIT OR OTHER EVIDENCE	
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice because applicant failed to provide a showing of good and sufficient reasons why the affidavit or was not earlier presented. See 37 CFR 1.116(e).	r other evidence is necessary and
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal ar showing a good and sufficient reasons why it is necessary and was not earlier presented. See 3	nd/or appellant fails to provide a
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry REQUEST FOR RECONSIDERATION/OTHER	
<ul> <li>11. The request for reconsideration has been considered but does NOT place the application in con See Continuation Sheet.</li> <li>12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).</li> </ul>	munion for anowance decause:
13. Other:	
/Frederick Krass/ /Marcos Sznaidman/ Supervisory Patent Examiner, Art Unit 1612	

Continuation of 3. NOTE: The new limitation in claims 1, 4, 6, 11 and 14: "consisting of" changes the scope of the claims and was not presented prior to the Final Office Action, and thus will require further consideration. The proposed amendment will require further consideration and search to determine if these new compositions are novel or nonobvious and if they fairly suggest, teach or disclose the treatment of respiratory diseases like COPD. Additionally, the removal of "to a patient in need thereof" changes the scope of the claims such that they are potentially read upon by any administration of the claimed compounds, necessitating consideration of a potential new rejection under 35 USC 102, and under 35 USC 112, second paragraph as well (since the claim could be considered incomplete insofar as the verb "administering" would have no object upon which to act).

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments that the newly amended claims are patentable over the prior art references are most at this time due to non-entry of the proposed amendment.